RheinCell teams up with RegMedNet to shine a spotlight on iPSCs
RegMedNet has just announced a new In Focus feature taking a close look at how induced pluripotent stem cells can catalyze the advancement of novel cell therapies. Prepared in collaboration with RheinCell experts, the feature explores biological, clinical and commercial characteristics of iPSCs as ideal starting materials.
With a video to introduce the topic, an infographic that sheds light on the advantages of iPSCs, and an informative interview with Boris Greber and Thomas Marx, the In Focus feature is an excellent starting point to gain knowledge about how iPSCs – especially HLA-homozyogous cell lines – constitute a universal "off-the-shelf" source of materials for a spectrum of cell therapies.
Check it out here!